Potential solutions for manufacture of CAR T cells in cancer immunotherapy

CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

Detalles Bibliográficos
Autores principales: Blache, Ulrich, Popp, Georg, Dünkel, Anna, Koehl, Ulrike, Fricke, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445013/
https://www.ncbi.nlm.nih.gov/pubmed/36064867
http://dx.doi.org/10.1038/s41467-022-32866-0
_version_ 1784783334756319232
author Blache, Ulrich
Popp, Georg
Dünkel, Anna
Koehl, Ulrike
Fricke, Stephan
author_facet Blache, Ulrich
Popp, Georg
Dünkel, Anna
Koehl, Ulrike
Fricke, Stephan
author_sort Blache, Ulrich
collection PubMed
description CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.
format Online
Article
Text
id pubmed-9445013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94450132022-09-07 Potential solutions for manufacture of CAR T cells in cancer immunotherapy Blache, Ulrich Popp, Georg Dünkel, Anna Koehl, Ulrike Fricke, Stephan Nat Commun Comment CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups. Nature Publishing Group UK 2022-09-05 /pmc/articles/PMC9445013/ /pubmed/36064867 http://dx.doi.org/10.1038/s41467-022-32866-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Blache, Ulrich
Popp, Georg
Dünkel, Anna
Koehl, Ulrike
Fricke, Stephan
Potential solutions for manufacture of CAR T cells in cancer immunotherapy
title Potential solutions for manufacture of CAR T cells in cancer immunotherapy
title_full Potential solutions for manufacture of CAR T cells in cancer immunotherapy
title_fullStr Potential solutions for manufacture of CAR T cells in cancer immunotherapy
title_full_unstemmed Potential solutions for manufacture of CAR T cells in cancer immunotherapy
title_short Potential solutions for manufacture of CAR T cells in cancer immunotherapy
title_sort potential solutions for manufacture of car t cells in cancer immunotherapy
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445013/
https://www.ncbi.nlm.nih.gov/pubmed/36064867
http://dx.doi.org/10.1038/s41467-022-32866-0
work_keys_str_mv AT blacheulrich potentialsolutionsformanufactureofcartcellsincancerimmunotherapy
AT poppgeorg potentialsolutionsformanufactureofcartcellsincancerimmunotherapy
AT dunkelanna potentialsolutionsformanufactureofcartcellsincancerimmunotherapy
AT koehlulrike potentialsolutionsformanufactureofcartcellsincancerimmunotherapy
AT frickestephan potentialsolutionsformanufactureofcartcellsincancerimmunotherapy

Ejemplares similares